LXEO

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company headquartered in New York, focused on developing breakthrough therapies to treat both hereditary and acquired diseases. Utilizing cutting-edge gene-editing technologies, Lexeo is advancing a diverse pipeline of innovative treatments designed to meet substantial unmet medical needs and improve patient outcomes. With its commitment to pioneering proprietary platforms, Lexeo is poised to be a transformative force in the rapidly evolving genetic medicine sector, positioning itself as an essential player for institutional investors seeking exposure to this dynamic field.